Lympho-vascular invasion in BRCA related breast cancer compared to sporadic controls by van Voss, Marise R Heerma et al.
van Voss et al. BMC Cancer 2010, 10:145
http://www.biomedcentral.com/1471-2407/10/145
Open Access RESEARCH ARTICLE
BioMed  Central
© 2010 van Voss et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research article Lympho-vascular invasion in BRCA related breast 
cancer compared to sporadic controls
Marise R Heerma van Voss1, Petra van der Groep1, Jos Bart3, Elsken van der Wall2 and Paul J van Diest*1
Abstract
Background: Germline mutations in the BRCA1 gene predispose to the development of breast cancer, exhibiting a 
specific histological phenotype. Identification of possible hallmarks of these tumors is important for selecting patients 
for genetic screening and provides inside in carcinogenetic pathways.
Since BRCA1-associated breast cancers have pushing borders that prevent them from easily reaching vessels and are
often of the medullary (like) type that is known to have a low rate of lympho-vascular invasion (LVI), we hypothesized
that absence of LVI could characterize BRCA1 related breast cancer.
Methods: A population of 68 BRCA1 related invasive breast cancers was evaluated for LVI by an experienced breast 
pathologist blinded to mutation status, and compared to a control group matched for age, grade and tumor type.
Results: LVI was present in 25.0% of BRCA1 related cases, compared to 20.6% of controls (P = 0.54, OR = 1.29, CI 0.58-
2.78).
Conclusion: LVI is frequent in BRCA1 germline mutation related breast cancers, but seems to occur as often in sporadic 
controls matched for age, grade and tumor type. Apparently, these hereditary cancers find their way to the blood and 
lymph vessels despite their well demarcation and often medullary differentiation.
Background
About 5-10% of all breast cancer cases are due to a hered-
itary predisposition. The two most important genes that,
when bearing a germline mutation, predispose to breast
cancer, are the BRCA1 and BRCA2 genes. It has been
estimated that 5.3% of breast cancers occurring in women
under forty years and 1.1% of breast cancers in women
from 50 to 70 years are due to mutations in either of these
genes[1]. Both genes are considered to be tumor suppres-
sor genes that play a role in DNA repair [2-6] and mam-
mary stem cell differentiation[7,8].
Mutation carriers have an increased life-time risk of
developing breast cancer of 57% and 40% and of develop-
ing ovarian cancer of 40% and 18% for BRCA1 and
BRCA2 respectively[9].
BRCA1 related breast carcinomas have a distinct histo-
pathological phenotype. They have been shown to be
more often of the ductal and medullary type, of high
grade and to show a high mitotic activity index (MAI)
and necrosis [10,11]. An expensive growth pattern is also
a prominent feature of this phenotype. Pushing margins
have been reported to be significantly more often present
and to cover a larger area of the tumor in BRCA1 and -2
related breast cancers[12,13]. In addition, specific immu-
nohistochemical, gene expression and genomic alteration
profiles have been described putting this hereditary sub-
group apart from other breast cancer subtypes. These
tumors usually do not express the estrogen and proges-
terone receptors and are almost always HER-2/neu nega-
tive ("triple negative")[10]. Furthermore, accumulation of
p53[10] and overexpression of vimentin[14], EGFR [15],
HIF-1α[16], p-cadherin, and cytokeratins 5/6 and 14[17]
are associated with BRCA1 mutations. At the gene-
expression level these tumors cluster together with the
basal-like subgroup[18]. BRCA2 related breast cancers
are most often of luminal type and seem phenotypically
harder to recognize[11].
Unraveling genotype, morphology and immunopheno-
type of BRCA-germline mutation related breast cancer
has several advantages. Established biomarkers help the
pathologist to recognize these hereditary cancers, which
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can help to trigger analyzing family history and to decide
on mutation testing in patients at borderline risk, based
on family history only. Tools that help to select patients
for screening are wanted, since genetic screening is time-
consuming and expensive. Further, an established pheno-
type can help to pin down the pathogenicity of so called
"unclassified variant" mutations. Lastly, insight into car-
cinogenetic pathways may offer opportunities to develop
new targeted therapies for treatment and prevention of
hereditary breast cancer.
Locoregional and systemic spread of breast cancer cells
to respectively the lymph nodes and distant organs
occurs after invasion of tumor cells into the lymphatic
channels and the blood vessels. Although lymphatics and
blood vessels of the breast can basically be discerned
using immunohistochemical markers, this is in practice
not usually done and lymphatic and blood vessel invasion
is lumped as "lympho-vascular invasion" (LVI). LVI is
present in approximately 15% of invasive ductal breast
carcinomas, but its frequency differs widely among stud-
ies (5-50%). It is unusual to find LVI in lobular carcino-
mas[19]. LVI correlates with the presence of lymph node
metastases[20,21] and is, not unexpectedly, a poor prog-
nostic sign [22-24]. We hypothesized that LVI is nega-
tively associated with BRCA1 germline mutations for
three reasons. First, BRCA1 associated breast cancers are
known to have pushing borders. Such an expansive
growth pattern would mean that adjacent structures are
pushed aside, rather than infiltrated, so that blood and
lymph vessels may not be easily reached and invaded by
tumor cells. In ER-negative breast cancer it has been
shown that the presence of pushing margins correlates
with the absence of LVI and lymph node negative sta-
tus[25]. In endometrial carcinomas LVI has also been
associated with a diffusely infiltrative and almost never
with an expansive growth pattern[26].
Second, since the presence of LVI strongly correlates
with lymph node metastases, low rates of LVI are likely to
result in relatively frequent negative axillary nodal status.
Indeed, a trend has been reported toward a higher per-
centage of lymph node negative, BRCA1-positive breast
cancers as compared with controls[27]. In addition, the
strong correlation between tumor size and nodal status
described for sporadic breast cancer patients, was absent
in BRCA1 mutation carriers[28].
Third, BRCA1 related breast cancers are frequently
(11-19%) of the medullary tumor type, in contrast to 1%
of sporadic cancers[29]. A high percentage of BRCA1
mutations has indeed been reported in medullary breast
carcinomas[30]. Medullary carcinomas are associated
with a significantly lower LVI rate of 6%[31].
Five studies have previously evaluated LVI in BRCA
related breast cancer, some finding more and some less
LVI compared to controls, but significance was not
reached [13,32-35], due to small populations (n = 8-32)
and lack of correction for confounders like grade, thus
not allowing definite conclusions.
We therefore set out to compare frequency of LVI in a




A population of 68 patients with hereditary invasive
breast cancer, due to a germline mutation in the BRCA1
gene, was studied. A control group of 68 breast cancer
patients unselected for family history and with no known
mutation (further denoted "sporadic") was selected by
case matching for age, tumor type and histologic grade as
much as possible. All tumors could be coupled to a tumor
with the same grade. The next step was matching for age,
using a window of 5 years. Some tumor types were so
rare, that after matching for age, no match for type could
be found. They were therefore matched to invasive ductal
carcinomas. Matching for these features was deemed
necessary because these characteristics are significantly
different between sporadic and BRCA related tumors and
have been shown to be associated with the presence of
LVI[36]. We excluded all "sporadic" cases for which a
strong family history of breast cancer in the pathology
report or electronic patient files was mentioned and all
cases of which cumulative breast cancer risk exceeded
30% based on family history in the patient file[37]. MAI
was assessed as before[38]. Growth pattern was reported
to be expansive if pushing margins were observed in
>50% of the tumor circumference[13]. Anonymous use of
redundant tissue for research purposes is part of the stan-
dard treatment agreement with patients in our hospi-
tals[39]. The protocol for use of the redundant tissue was
approved by the science committee of the UMC Utrecht
Biobank. Clinical data were retrieved from the pathology
report and patient files. 71.3% of patients underwent an
axillary lymph node dissection, the remaining 28.7% only
underwent a sentinel node biopsy Breast conserving ther-
apy was performed in similar rates in hereditary and spo-
radic patients.
Lympho-vascular invasion
All available Hematoxylin-eosin (H&E) stained slides of
all tumors were retrieved from our archive and screened
for LVI by an experienced breast pathologist (PvD)
blinded to BRCA mutation status. For the determination
of LVI status we used criteria for identification as postu-
lated by Rosen: "Evaluation is limited to tissue peripheral
to the carcinoma, intralymphatic tumor emboli usually
do not conform exactly to the space in which they lie,
endothelial nuclei should be present and coexistent blood
vessels are confirmatory evidence."[40]van Voss et al. BMC Cancer 2010, 10:145
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Since many of the hereditary cases and some of the spo-
radic cases were referrals for which only one slide with
tumor was available, we selected for each matched pair
(case and control) the same number of slides to end up
with a comparable number of slides assessed for LVI in
both groups. For all patients with only one slide available,
we selected for the match the H&E from the block on
which immunohistochemistry (IHC) had been done. If no
IHC had been done, the slide with the largest tumor area
was selected. Although not including all slides might
result in some false negatives and thereby lead to an
underestimation of LVI frequency in our study group, this
would apply to both the hereditary and sporadic in a sim-
ilar manner and thereby does not influence our compari-
son between both groups.
Statistics
Frequencies of LVI in hereditary cases and sporadic con-
trols were compared by Chi-square test and Fischer exact
test and odds ratios (OR) were calculated with 95% confi-
dence intervals. Continuous data for both groups (e.g.
MAI) were compared by Mann-Whitney U test. When
f e a t u r e s  w e r e  s i g n i f i c a n t l y  a s s o c i a t e d  w i t h  b o t h  B R C A
mutation status and the presence of LVI, statistical analy-
sis of these possible confounders took place by calculat-
ing ORs stratified for specific subgroups (corrected by
Mantel-Haenszel procedure) and logistic regression for
significant features. All statistical analyses were per-
formed using SPSS 15.0.
Results
Patients and tissues
Anonymous use of redundant tissue for research pur-
poses is part of the standard treatment agreement with
patients in our hospital [41], in compliancy with the Hel-
sinki Declaration. The research protocol for this study
was approved by the Scientific Advisory Committee of
the UMC Utrecht Biobank.
In the BRCA1 group, median tumor size was 1.8 cm
compared to 2.6 for controls (p = 0.003), median MAI
was 22 vs 20 in controls (n.s.), and median age was 40 in
both cases and controls (n.s.). Invasive ductal carcinomas
were slightly more prevalent in the sporadic group (n.s.).
Table 1 shows the further features of the BRCA1 popula-
tion and the sporadic control group. BRCA1 related
patients more frequently had negative lymph nodes
(67.2% compared to 50.8% in controls), but this difference
was not statistically significant (P = 0.06). Expansive
growth pattern was present in 47% of BRCA1 related
tumors, compared to 41% in sporadic controls (n.s.). Mul-
tifocality (more than one invasive intramammary tumor
nodule) was present in 21.8% of sporadic tumors, com-
pared to 25% of BRCA1 related tumors (n.s.). All BRCA1
related carcinomas had a negative HER-2/neu receptor
status when assessed, whereas in the control group 23.5%
was positive (P = 0.005). Both ER and PR receptor status
were more often negative in the BRCA1 related group
(72.7% and 75.4% for ER and PR respectively, compared
to 48.3% and 54.5% in controls; P = 0.005 and P = 0.016,
respectively).
Lympho-vascular invasion
Frequencies of LVI in the BRCA1 related breast cancer
and sporadic controls are shown in table 1. 25.0% of
hereditary cases were positive for LVI, compared to 20.6%
of controls, which was not statistically significant (P =
0.54, OR = 1.29, 95% CI = 0.58-2.78). Also when stratify-
ing for tumor type, we did not find a significant difference
between sporadic and BRCA related carcinomas (table 2).
There was a much lower rate of LVI in medullary and
metaplastic carcinomas.
No significant confounders were identified by stratified
analysis and ORs, adjusted for confounding by Mantel
Haenszel procedure, were not significantly different from
the crude ORs. Therefore, further analysis of confounders
by means of logistic regression was deemed unnecessary.
Discussion
The aim of this study was to evaluate the absence of LVI
as a putative biomarker in BRCA1 germline mutation
related breast cancer. Our data did however not show the
expected lower rate of LVI in BRCA related tumors.
Five studies have evaluated LVI in BRCA related breast
cancer. None of the studies found a significant correlation
between mutation status and LVI. Only one study statisti-
cally corrected for histologic tumor grade, by means of
stratification[32]. This study compared 32 BRCA1 related
tumors to 334 unmatched controls. LVI was reported in
31.6% and 25.3% of the cases for BRCA1 related and spo-
radic tumors, respectively. This result was not significant
(P = 0.29). Correction for other possible confounders (e.g.
age, tumor type and size) did not take place. In four other
studies no matching or statistical correction for con-
founding was performed at all[13,33-35]. Relatively small
populations evaluated (n = 8-32), in addition to the lack
of correction for grade and other confounders make it
impossible to draw definite conclusions from these five
studies.
Rates of LVI in the present study (22.8%) were above
the average rate described in literature (15%)[19]. We had
i n d e e d  e x p e c t e d  t o  f i n d  a  h i g h e r  r a t e  o f  L V I  t h a n
described in literature, since our population consisted
mostly of high-grade carcinomas and high grade has been
associated with higher rates of LVI. In populations con-
sisting of solely grade 3 breast cancers, 35-46% of patients
were reported to contain LVI[22,42-44]. In three of these
four studies immunohistochemical staining for endothe-
lial walls was used for identification of LVI, which might
explain the higher rates found in these specific studies
compared to our study employing just H&E[22,43,44].van Voss et al. BMC Cancer 2010, 10:145
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Table 1: Characteristics of BRCA1 related breast cancers and sporadic controls evaluated for frequency of lympho-
vascular invasion
Sporadic control 
group (n = 68)
BRCA1 group (n = 68)
Number Percentage Number Percentage P-value OR 95% CI
Tumour Type invasive ductal carcinoma 58 85.3% 55 80.9% 0.83
invasive (ducto)lobular carcinoma 3 4.4% 3 4.4%
invasive medullary and 
metaplastic carcinoma
7 10.3% 10 14.7%
Histologic grade 1 3 4.4% 2 2.9% 0.88a
2 13 19.1% 14 20.6%
3 52 76.5% 52 76.5%
Tumour size <2 cm 24 35.3% 37 59.4% 0.02a
2-5 cm 36 52.9% 22 35.9%




N0 33 50.8% 39 67.2% 0.06a
N1 21 32.3% 17 29.3%
N2 9 13.8% 1 1.7%
N3 2 3.1% 1 1.7%
unknown 3 10
Growth pattern infiltrative 40 58.8% 36 52.9% 0.49 1.31 0.64-2.50
expansive 28 41.2% 32 47.1%
HER-2/neu status negative 26 76.5% 31 100.0% 0.005b
positive 8 23.5% 0 0.0%
unknown 34 37
ER status negative 28 48.3% 48 72.7% 0.005a 0.38 0.18-0.79
positive 30 51.7% 18 27.3%
unknown 10 2
PR status negative 30 54.5% 49 75.4% 0.016a 0.42 0.19-0.92




negative 54 79.4% 51 75.0% 0.54a 1.29 0.58-2.87
positive 14 20.6% 17 25.0%
a. P-value obtained with a Chi-square test. b. P-value obtained with a Fischer's exact testvan Voss et al. BMC Cancer 2010, 10:145
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Further, there is no real consensus on the definition of
LVI, sometimes including intratumoral LVI, interob-
server discordance has been reported [45-47] and case
selection differed between studies, possibly contributing
to the wide range of frequencies reported. Retraction
artefacts and intraductal carcinoma are in some cases
hard to distinguish from LVI and can lead to false posi-
tives whereas tumor emboli filling up the entire lumen of
a vessel sometimes make it hard to detect LVI and may
result in false negatives. However, topographic condi-
tions, like other accompanying vessels usually help mak-
ing the diagnosis LVI[45]. In addition, when LVI seems
questionable at one location very often there is clearer
LVI present elsewhere in the section.
To deal with interobserver discordance as mentioned,
the same observer evaluated all slides. Therefore, poten-
tial interobserver bias is of little influence on our compar-
ison between sporadic and hereditary breast cancer. In
addition, several studies have shown that regarding
equivocal cases as negative did not influence the predic-
tive value of LVI[45,46].
An explanation for the fact that we found lower LVI fre-
quencies, than described in the literature for grade 3 can-
cers, may lie in that fact that we did not evaluate all slides
of all tumors, in order to match for number of evaluated
slides per case, so that we may have missed LVI in cases
where it is not present in all the slides. To get an impres-
sion of the magnitude of this potential reduction, we also
assessed LVI in all slides available in the sporadic group.
We then found an about 1.5 times higher rate of LVI
(30.9%) if we considered all available slides in the sporadic
group instead of only those slides used after slide number
matching.
In order to find a L VI effect contributable to BRCA1
mutation and not to another feature associated with the
BRCA1 phenotype, it was deemed necessary to match for
features associated with LVI. Unfortunately, this match-
ing has a downside. By case-matching to select controls,
we likely preferentially select some hidden BRCA1/2
mutation carriers (age, histologic type and grade effect),
as well as some tumors that have no known BRCA muta-
tion but show a similar phenotype (type, grade effect) by
e.g. promoter hypermethylation of BRCA1/2 or a muta-
tion in another gene involved in the BRCA pathway. 9-
22% of sporadic breast cancers have been described to
show promoter hypermethylation of BRCA1 or loss of
heterozygosity at the BRCA1 locus and these tumors are
largely ER and PR negative, of ductal and medullary type,
and high grade [48-52]. These are all also features of
tumors with a mutation in BRCA1. One study selected 7
sporadic tumors with a BRCA1 phenotype, and found
that 3 out of 7 showed promoter hypermethylation of
BRCA1[53]. Selecting "sporadic" controls with a BRCA1
like phenotype might make it harder to find differences
between sporadic and BRCA related carcinomas. This
might explain why we did not find the expected correla-
tion between expansive growth pattern and BRCA1
mutation status as was described in literature. The
absence of a higher frequency of pushing margins in our
BRCA1 related group, is a possible explanation for the
unexpected similar rates of LVI found in both groups.
W e further looked into features that were associated
with both L VI and BRCA mutation status such as age,
tumor type, tumor size, nodal status, grade, ER and PR
[19,21,22,42-44], to exclude and correct for possible con-
founders. No significant differences were found between
cases and controls for age, nodal status and grade. Con-
tradictory with literature, we did not find a significantly
higher MAI in our hereditary group. Since cases were
matched for tumor grade and MAI (as a constituent of
grade) strongly correlates with grade, a difference was not
expected here. Invasive ductal carcinomas were slightly
more prevalent in the sporadic group. This is due to the
fact that case matching could not always be performed
for type in the case of rare tumor types and these were
matched to ductal carcinomas. Stratification for tumor
type shows a much lower rate of LVI in medullary and
metaplastic carcinomas, which is consistent with litera-
ture[31]. A significantly lower rate of ER, PR and HER-2/
neu expression was found in the BRCA1 related group.
This is consistent with what we know from literature
about BRCA1 related tumors, mostly showing a triple-
negative receptor status[54]. ER and PR negative status
have been associated with high LVI rates. No significant
correlation between HER-2/neu status and LVI has been
described [19,55]. In our study ER status was not signifi-
cantly associated with LVI and neither was PR or HER-2/
neu  status. When stratified separately for ER, PR and
HER-2/neu status, no significant differences for LVI sta-
tus between cases and controls were found.
In our control group tumor size was slightly larger than
in the BRCA1 related group. This has not been reported
in literature. Since several studies noted that tumor size is
significantly associated with LVI, this is a possible con-
founder. These studies reported high frequencies (58-
69%) of LVI in tumors with a diameter bigger than 5
cm[42,43], although the one reporting the highest rates
used immunohistochemistry to detect LVI. In our study
LVI in tumors bigger than 5 cm was not significantly
higher, so this does not likely play an important role here.
The significant difference in tumor size between cases
and controls was largely based on a difference in distribu-
tion between the group up to 2 cm and the group from 2-
5 cm, but between these groups no significant differences
in LVI rates were found.
Conclusions
LVI seems to occur as much in BRCA1 germline muta-
tion related breast cancers as in sporadic controls. Appar-
ently, these hereditary cancers find their way to the bloodvan Voss et al. BMC Cancer 2010, 10:145
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and lymph vessels despite their well demarcation and
often medullary type differentiation.
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